TY - JOUR
T1 - Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19
T2 - A systematic review
AU - Joseph, Betsy Ann
AU - Dibas, Mahmoud
AU - Evanson, Kirk W.
AU - Paranjape, Geeta
AU - Vegivinti, Charan Thej Reddy
AU - Selvan, Pragadeesh Thamarai
AU - Saravu, Kavitha
AU - Gupta, Nitin
AU - Pulakurthi, Yashwitha Sai
AU - Keesari, Praneeth Reddy
AU - Varsha, Sriram
AU - Chittajallu, Spandana
AU - Dmytriw, Adam A.
AU - Reierson, Natalie L.
AU - Mikoff, Nick
AU - Kamrowski, Shelby
AU - Schmidt, Megan
AU - Davis, Amber R.
AU - Pederson, John M.
AU - Mishra, Hemant K.
AU - Touchette, Jillienne C.
AU - Kallmes, Kevin
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with Cornonavirus disease 19 (COVID-19) to assess the efficacy of LPV/r for the treatment of COVID-19. Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studies, single-armed studies, not written in English, not relevant to the topic, or published before May 2020. The included outcomes were viral clearance as measured by reverse-transcription polymerase chain reaction (RT-PCR) negativity and/or improvement on chest computed tomography (CT), mortality, and adverse events. Results: Among 858 total studies, 16 studies met the inclusion criteria and were included in the qualitative review. These studies consisted of 3 randomized control trials, 3 open-label trials, and 10 observational studies. Most of these studies did not report positive clinical outcomes with LPV/r treatment. Conclusion: The systematic review revealed insufficient evidence of effectiveness and clinical benefit of LPV/r in the treatment of COVID-19 patients. Specifically, LPV/r does not appear to improve clinical outcome, mortality, time to RT-PCR negativity, or chest CT clearance in patients with COVID-19.
AB - Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with Cornonavirus disease 19 (COVID-19) to assess the efficacy of LPV/r for the treatment of COVID-19. Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studies, single-armed studies, not written in English, not relevant to the topic, or published before May 2020. The included outcomes were viral clearance as measured by reverse-transcription polymerase chain reaction (RT-PCR) negativity and/or improvement on chest computed tomography (CT), mortality, and adverse events. Results: Among 858 total studies, 16 studies met the inclusion criteria and were included in the qualitative review. These studies consisted of 3 randomized control trials, 3 open-label trials, and 10 observational studies. Most of these studies did not report positive clinical outcomes with LPV/r treatment. Conclusion: The systematic review revealed insufficient evidence of effectiveness and clinical benefit of LPV/r in the treatment of COVID-19 patients. Specifically, LPV/r does not appear to improve clinical outcome, mortality, time to RT-PCR negativity, or chest CT clearance in patients with COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85097826227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097826227&partnerID=8YFLogxK
U2 - 10.1080/14787210.2021.1848545
DO - 10.1080/14787210.2021.1848545
M3 - Review article
C2 - 33187459
AN - SCOPUS:85097826227
SN - 1478-7210
VL - 19
SP - 679
EP - 687
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 6
ER -
